Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods

被引:52
|
作者
Houck, PR
Mazuradar, S
Koru-Sengul, T
Tang, G
Mulsant, BH
Pollock, BG
Reynolds, CF
机构
[1] UPMC, Hlth Syst, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15260 USA
[4] VA Pittsburgh Hlth Care Syst, Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA 15213 USA
关键词
intent-to-treat; missing data; mixed model; multiple imputation; maximum likelihood; depression;
D O I
10.1016/j.psychres.2004.08.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The selection of a method for estimating treatment effects in an intent-to-treat analysis from clinical trial data with missing values often depends on the field of practice. The last observation carried forward (LOCF) analysis assumes that the responses do not change after dropout. Such an assumption is often unrealistic. Analysis with completers only requires that missing values occur completely at random (MCAR). Ignorable maximum likelihood (IML) and multiple imputation (MI) methods require that data are missing at random (MAR). We applied these four methods to a randomized clinical trial comparing anti-depressant effects in an elderly depressed group of patients using a mixed model to describe the course of the treatment effects. Results from an explanatory approach showed a significant difference between the treatments using LOCF and IML methods. Statistical tests indicate violation of the MCAR assumption favoring the flexible IML and MI methods. IML and MI methods were repeated under the pragmatic approach, using data collected after termination of protocol treatment and compared with previously reported results using piecewise splines and rescue (treatment adjustment) pragmatic analysis. No significant treatment differences were found. We conclude that attention to the missing-data mechanism should be an integral part in analysis of clinical trial data. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 50 条
  • [41] Novel non-linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methods
    Wang, Guoqiao
    Wang, Whedy
    Mangal, Brian
    Liao, Yijie
    Schneider, Lon
    Li, Yan
    Xiong, Chengjie
    Mcdade, Eric
    Kennedy, Richard
    Bateman, Randall
    Cutter, Gary
    [J]. STATISTICS IN MEDICINE, 2024, 43 (15) : 2987 - 3004
  • [42] Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data
    Tomazos, Ioannis
    Hatswell, Anthony J.
    Cataland, Spero
    Chen, Peter
    Freemantle, Nick
    Lommele, Asa
    Deighton, Kevin
    Knowles, Emma
    Sheerin, Neil S.
    Rondeau, Eric
    [J]. CLINICAL NEPHROLOGY, 2022, 97 (05) : 261 - 272
  • [43] Comparative clinical data for gingivitis treatment using gels from Ocimum sanctum (Tulsi) and chlorhexidine (CHX)
    Deepika, B. A.
    Ramamurthy, Jaiganesh
    Jayakumar, Nadathur Duraisamy
    Kumar, S. Rajesh
    [J]. BIOINFORMATION, 2021, 17 (12) : 1091 - 1098
  • [44] Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods
    Dunn, G
    Maracy, M
    Tomenson, B
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2005, 14 (04) : 369 - 395
  • [45] Addressing missing values in routine health information system data: an evaluation of imputation methods using data from the Democratic Republic of the Congo during the COVID-19 pandemic
    Shuo Feng
    Celestin Hategeka
    Karen Ann Grépin
    [J]. Population Health Metrics, 19
  • [46] Addressing missing values in routine health information system data: an evaluation of imputation methods using data from the Democratic Republic of the Congo during the COVID-19 pandemic
    Feng, Shuo
    Hategeka, Celestin
    Grepin, Karen Ann
    [J]. POPULATION HEALTH METRICS, 2021, 19 (01)
  • [47] PREDICTION OF TREATMENT EFFECTS FOR INDIVIDUAL CANCER PATIENTS USING DATA FROM RANDOMIZED CLINICAL TRIALS
    van Kruijsdijk, R. C. M.
    Visseren, F. L. J.
    Dingemans, A. C.
    Groen, H. J. M.
    Aerts, J. G.
    van der Graaf, Y.
    Smit, E. F.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [48] Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases
    Wendling, T.
    Jung, K.
    Callahan, A.
    Schuler, A.
    Shah, N. H.
    Gallego, B.
    [J]. STATISTICS IN MEDICINE, 2018, 37 (23) : 3309 - 3324
  • [49] Statistical Methods for Estimating Treatment Effects From Randomized Clinical Trials in the Presence of Non-Randomized Post-Study Therapies
    Leon, Larry F.
    Day, Bann-Mo
    Hu, Sylvia
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 225 - 225
  • [50] Treatment effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people underrepresented from the ontarget trial: Analysis of routinely collected data using trial replication methods
    Baptiste, Paris J.
    Wong, Angel
    Schultze, Anna
    Cunnington, Marianne
    Mann, Johannes F.
    Clase, Catherine
    Leyrat, Clemence
    Tomlinson, Laurie
    Wing, Kevin
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 553 - 553